)
Company Research30 Jun 2025
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
AbbVie
AbbVie (ABBV) investor relations material
AbbVie Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary10 Mar, 2026
Growth outlook and financial performance
Guidance targets $67 billion in revenue for 2026, with high single-digit growth expected through the decade.
SKYRIZI and RINVOQ drive over 20% combined growth, with significant headroom for further market share gains.
Neuroscience is the second fastest-growing area, with migraine and Parkinson’s franchises expected to exceed $5 billion each in peak sales.
Operating margin expansion continues, with EPS growth outpacing revenue and ongoing SG&A efficiencies.
R&D investment remains at 14%-15% of sales, increasing in absolute terms to support long-term growth.
Product and pipeline updates
SKYRIZI maintains strong new patient share in IBD, with 75% in first-line naive patients and new subcutaneous data to be filed soon.
RINVOQ label update in Q3 last year allows second-line use after biologic failure, enhancing its positioning in IBD.
Subcutaneous SKYRIZI filing expected in the coming months, with potential approval and launch early next year.
Amylin candidate shows nearly 10% weight loss at 12 weeks in a non-obese, mostly male population; phase Ib and II trials planned for broader populations.
Multiple phase III and II readouts expected this year across immunology, oncology, and neuroscience, including key assets in HS, IBD, multiple myeloma, and depression.
Competitive landscape and strategy
Competitive threats in IBD, such as Tremfya and icotrokinra, are factored into guidance, with continued confidence in market share growth.
Dual asset approach in IBD (SKYRIZI front-line, RINVOQ second-line) strengthens portfolio positioning.
HS market is under-penetrated; RINVOQ and lutikizumab phase III trials target both naive and biologic-failure patients.
Oncology pipeline includes T-cell engagers, ADCs, and bispecifics, with several assets targeting ovarian, lung, prostate, and colorectal cancers.
Neuroscience pipeline includes migraine expansion and a promising short-acting psychedelic for depression.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next AbbVie earnings date
Q1 202624 Apr, 2026
AbbVie
Next AbbVie earnings date
Q1 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Innovative therapies for improved health worldwide
Abbvie is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's mission is to address complex health challenges and improve the lives of people around the world. Abbvie's primary areas of therapeutic focus include immunology, oncology, neuroscience, virology, and general medicine.
Abbvie's business model revolves around research and development (R&D) to discover and advance novel therapies, obtaining regulatory approvals for its products, and commercializing them in global markets. The company's revenue primarily comes from the sales of its pharmaceutical products.
Structural tailwinds
Opportunities for Abbvie lie in several areas. The global healthcare market continues to grow as the population ages, and there is a constant need for effective treatments for various diseases. Abbvie can leverage its R&D capabilities to develop innovative therapies that address unmet medical needs, expanding its product portfolio and capturing market share.
Furthermore, Abbvie has a robust pipeline of potential new drugs, which presents opportunities for future growth. By successfully developing and commercializing these pipeline candidates, the company can strengthen its market position and drive revenue growth.
Challenges faced by Abbvie include the competitive nature of the pharmaceutical industry. There are other established pharmaceutical companies and biotech firms developing treatments for similar indications. Abbvie needs to navigate patent expirations, competition from generic drugs, and the potential impact of biosimilars on its revenue.
Additionally, the regulatory environment poses challenges for Abbvie. Obtaining regulatory approvals for new drugs is a complex and time-consuming process, and the company must meet stringent safety and efficacy requirements set by regulatory authorities worldwide.
Three listed peers to Abbvie
Johnson & Johnson, a multinational healthcare conglomerate that operates in various segments, including pharmaceuticals, medical devices, and consumer health. It develops and sells a wide range of products and therapies across multiple therapeutic areas.
The leading global pharmaceutical company Pfizer that develops, manufactures, and markets a diverse portfolio of prescription drugs, vaccines, and consumer healthcare products. It has a strong presence in various therapeutic areas, including oncology, immunology, and rare diseases.
Eli Lilly and Company, a global pharmaceutical company that focuses on developing and commercializing innovative medicines in areas such as oncology, diabetes, neuroscience, and immunology. The company is known for its expertise in biotechnology and has a strong pipeline of potential new drugs.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage